Journal Article

FZJ-2020-02401

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Imaging challenges following newer treatment options: Are companion diagnostics required in neurooncology?

Galldiks, N. (Corresponding author)FZJ* ; Lohmann, P.FZJ* ; Langen, K.-J.FZJ*

2020
Taylor & Francis Group Abingdon

This record in other databases:    

Please use a persistent id in citations: http://hdl.handle.net/2128/25600  doi:10.1080/14737159.2020.1782191

Abstract: Contrast-enhanced MRI is the method of choice for follow-up imaging in patients with brain tumors, but its specificity is low despite outstanding spatial resolution [1,2]. Importantly, the differentiation of treatment-related changes from actual tumor progression following newer treatment options such as immunotherapy using checkpoint inhibitors or vaccines is challenging by anatomical MRI alone [2–4]. Specifically, inflammation with intratumoral T-cell infiltrates triggered by immunotherapy may lead to highly variable MR imaging findings including contrast enhancement that may suggest tumor progression. Moreover, neuroimaging changes induced by these treatment options may also hamper a reliable response assessment.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)
2. Physik der Medizinischen Bildgebung (INM-4)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2020

---

Database coverage:
; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---